Thrombocytopenia is commonly seen in myelodysplastic syndrome (MDS) patients, and
bleeding complications are a major cause of morbidity and mortality. Thrombocytopenia is …

Thrombocytopenia in patients with myelodysplastic syndromes (MDS) is a frequent cause of
haemorrhage‐related morbidity and mortality, and is associated with increased risk of …

Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Patients with myelodysplastic syndrome (MDS) who present with isolated thrombocytopenia
(TCP) constitute a poorly described subgroup. The aim of the present study was to …

Myelosuppression, one of the most common toxicities of chemotherapy, results in varying
degree of cytopenias. While neutropenia and anemia have been reduced with the currently …

Thrombocytopenia, common in leukemias and myelodysplastic syndromes (MDS), is
responsible for increased risk of bleeding and delay of therapy. Platelet transfusions …

Abstract Abstract 923 Introduction: The increased risk of bleeding in myelodysplastic
syndromes (MDS) is due to low platelet (PLT) counts and abnormalities of PLT morphology …

Summary Thrombocytopenia is common (40–65%) and potentially serious in
myelodysplastic syndromes (MDS). A systematic review was conducted to determine the …

Romiplostim can improve platelet counts in about 50% of patients with low‐or intermediate 1‐
risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long‐term …

Abstract Abstract 3822 Background: Patients with myelodysplastic syndromes (MDS) or
acute myeloid leukemia (AML) commonly experience severe thrombocytopenia with a high …